Recce's R327 found effective against E.coli during clinical trial
Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.